NYMC Faculty Publications

Novel Oral Anticoagulants in the Peri-endoscopic Period

DOI

10.1097/CRD.0000000000000149

Journal Title

Cardiology in Review

First Page

223

Last Page

229

Document Type

Article

Publication Date

September 2017

Department

Medicine

Abstract

Millions of patients in the United States are currently prescribed some form of anticoagulation therapy. Recently, novel oral anticoagulants (NOACs), including direct thrombin inhibitors and direct factor Xa inhibitors, have begun to replace warfarin as the drugs of choice for anticoagulation. As the use of these medications becomes more widespread, it is increasingly important for gastroenterologists to understand the risks associated with performing endoscopic procedures on patients who are taking NOACs. In this review, we provide an overview of the NOACs, as well as current guidelines from international societies regarding the management of patients scheduled to undergo endoscopic procedures who are prescribed these medications. Finally, we offer a perspective on future studies required to adequately investigate and characterize the effects that these drugs have on a patient's risk for bleeding in the peri- and/or post-procedural timeframes.

Link to Full Text

Share

COinS